Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Sep;41(9):1953–1956. doi: 10.1128/aac.41.9.1953

High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks.

B Ji 1, P Jamet 1, S Sow 1, E G Perani 1, I Traore 1, J H Grosset 1
PMCID: PMC164043  PMID: 9303392

Abstract

Fifty-one lepromatous leprosy patients, all of whom had relapsed after previous dapsone (DDS) monotherapy, were treated between 1990 and 1991 with 600 mg of rifampin (RMP) plus 400 mg of ofloxacin (OFLO) daily for 4 weeks, and the great majority of the patients were followed up at least once a year after completion of the treatment. After only 173 patient-years of follow-up, 5 relapses had been detected; the overall relapse rate was 10.0% (confidence limits, 1.7 and 18.3%), or 2.9 relapses (confidence limits, 0.4 and 5.4) per 100 patient-years. The unacceptably high relapse rate indicated that 4 weeks of treatment with daily RMP-OFLO was unable to reduce the number of viable Mycobacterium leprae organisms to a negligible level. In addition, the M. leprae from one of the relapses were proved to have multiple resistance to DDS, RMP, and OFLO. To avoid further relapses, the follow-up was terminated and the great majority of the patients were retreated with the standard 2-year multidrug therapy from 1994. No further relapse has been diagnosed since the beginning of retreatment.

Full Text

The Full Text of this article is available as a PDF (171.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cambau E., Perani E., Guillemin I., Jamet P., Ji B. Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae. Lancet. 1997 Jan 11;349(9045):103–104. doi: 10.1016/S0140-6736(05)60888-4. [DOI] [PubMed] [Google Scholar]
  2. Gelber R. H., Levy L. Detection of persisting Mycobacterium leprae by inoculation of the neonatally thymectomized rat. Int J Lepr Other Mycobact Dis. 1987 Dec;55(4 Suppl):872–878. [PubMed] [Google Scholar]
  3. Grosset J. H., Guelpa-Lauras C. C., Bobin P., Brucker G., Cartel J. L., Constant-Desportes M., Flageul B., Frédéric M., Guillaume J. C., Millan J. Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin. Int J Lepr Other Mycobact Dis. 1989 Sep;57(3):607–614. [PubMed] [Google Scholar]
  4. Grosset J. H., Guelpa-Lauras C. C., Perani E. G., Beoletto C. Activity of ofloxacin against Mycobacterium leprae in the mouse. Int J Lepr Other Mycobact Dis. 1988 Jun;56(2):259–264. [PubMed] [Google Scholar]
  5. Grosset J. H., Ji B. H., Guelpa-Lauras C. C., Perani E. G., N'Deli L. N. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis. 1990 Jun;58(2):281–295. [PubMed] [Google Scholar]
  6. Jamet P., Blanc L., Fayne O. C., Traore I., Bobin P. Relapses after a single dose of rifampin in skin-smear negative multibacillary patients after dapsone monotherapy. Int J Lepr Other Mycobact Dis. 1994 Jun;62(2):209–214. [PubMed] [Google Scholar]
  7. Jamet P., Ji B. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group. Int J Lepr Other Mycobact Dis. 1995 Jun;63(2):195–201. [PubMed] [Google Scholar]
  8. Ji B. H. Drug resistance in leprosy--a review. Lepr Rev. 1985 Dec;56(4):265–278. [PubMed] [Google Scholar]
  9. Ji B., Jamet P., Perani E. G., Bobin P., Grosset J. H. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J Infect Dis. 1993 Jul;168(1):188–190. doi: 10.1093/infdis/168.1.188. [DOI] [PubMed] [Google Scholar]
  10. Ji B., Jamet P., Perani E. G., Sow S., Lienhardt C., Petinon C., Grosset J. H. Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Antimicrob Agents Chemother. 1996 Sep;40(9):2137–2141. doi: 10.1128/aac.40.9.2137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ji B., Perani E. G., Petinom C., Grosset J. H. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrob Agents Chemother. 1996 Feb;40(2):393–399. doi: 10.1128/aac.40.2.393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ji B., Perani E. G., Petinom C., N'Deli L., Grosset J. H. Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Antimicrob Agents Chemother. 1994 Apr;38(4):662–667. doi: 10.1128/aac.38.4.662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Levy L., Shepard C. C., Fasal P. The bactericidal effect of rifampicin on M. leprae in man: a) single doses of 600, 900 and 1200 mg; and b) daily doses of 300 mg. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):183–187. [PubMed] [Google Scholar]
  14. Ridley D. S., Jopling W. H. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966 Jul-Sep;34(3):255–273. [PubMed] [Google Scholar]
  15. Traore I., Ji B., Lienhardt C., Bobin P., Grosset J. Determination of the minimal effective dosages of ofloxacin and sparfloxacin against M. leprae in the mouse foot pad system. Int J Lepr Other Mycobact Dis. 1996 Jun;64(2):142–145. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES